Research on Pegasys and PegIntron
2008
Click here for
:2007-2004
May
Final Results of the Phase IIIb IDEAL Study
(Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL
PegInterferon Therapy) -
Peginterferon Alfa-2a (Pegasys) plus Ribavirin versus
Peginterferon alfa-2b (Pegintron) Plus Ribavirin in Naive Patients with
Chronic HHCV Infection: Results of a Prospective Randomized Trial
-
FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2
AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED
RIBAVIRIN COMBINATION
HALT-C Study Design Flawed
-
April
COLCHICINE VERSUS
PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR
COPILOT TRIAL
Pegylated Interferon Maintenance Demonstrates Benefits
for Hepatitis C Patients with Portal Hypertension
RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN
INDEPENDEND PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF
HEPATITIS C GENOTYPE 2/3 (NORDYNAMIC TRIAL)
Factors Predicting Response to Therapy for
Chronic Hepatitis C
-
Use of Different Pegylated Interferon/Ribavirin
Regimens after Rapid Virological Response Does Not Affect Sustained Response
Rate
Liver Gene Expression Predicts Response to Pegylated
Interferon plus Ribavirin
FDA Approves Label Revisions Recommending New Robetol (ribavirin)
Weight-Based Dosing Regimen: PEGINTRON PLUS WEIGHT-BASED REBETOL (ribavirin)
RESULTED IN HIGHER SVR THAN FLAT DOSING; LOW RELAPSE RATES IN PATIENTS WITH
CHRONIC HEPATITIS C. Schering Plough press release
-
Adult respiratory distress syndrome after
treatment with pegylated interferon alpha-2a and ribavirin.
Gastroenterologists' perceptions of need and
availability of psychiatric services for patients
with hepatitis C.
Quality-of-Life Tradeoffs for Hepatitis C Treatment:
Do Patients and Providers Agree?
March
FDA Approves New Weight-Based Dosing Regimen
for PegIntron plus Ribavirin
Use of Different Pegylated Interferon/Ribavirin
Regimens after Rapid Virological Response Does Not Affect Sustained Response
Rate
Pathology of Chronic Hepatitis C in Children: Peds-C
Trial
Glucose >100 mg/dl Reduces Interferon/RBV SVR
-
On-treatment responses at weeks 4 and 12 can be used
to predict sustained virologic response rates in HIV HCV co-infected
patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS)
-
Adjustment of Treatment Duration Based on
Early Response
IDEAL
Trial Results
Final Results of the Phase IIIb IDEAL Study
(Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL
PegInterferon Therapy) - May 08
The IDEAL (Individualized Dosing
Efficacy vs. Flat Dosing to Assess optimal
pegylated interferon therapy)
SVR and Disease Progression
Treatment of Hepatitis C Reduces Incidence of Non-Hodgkin's Lymphoma
-
-February
You must register with clinical
care options to view the following slide shows
Source: New Management Strategies for HCV
Nonresponders and Relapsers
Learn about the causes of nonresponse and
strategies for individualizing treatment in patients with hepatitis C.
Source: Drug Resistance in Chronic Hepatitis
B: From Definitions to Management Strategies
Source: CCO Independent Conference Coverage
of the 2007 Annual Meeting of the American Association for the Study of
Liver Diseases*
We are pleased to announce Donna Fanelli MSN NP
has joined us in
answering your questions about HCV and
treatment.
Click below to Ask Donna your HCV questions
 ASK
DONNA J.C FANELLI MSN, NP
You will need to Join our
forum
with a quick registration
|
Donna J. C. Fanelli, MSN, NP-C, Medical Director of
Primary Health and Wellness Center, LLC, in Milburn,
NJ and Senior Clinical Research Coordinator of
Gastroenterology Research Associates, LLC, in Cedar
Knolls, NJ. She is certified as an Acute Care Nurse
Practitioner, an Adult Nurse Practitioner, and a
certified Sexual Assault Forensic Examiner.
We are very pleased to provide
information in this forum. The information provided
is for general educational purposes only and is
intended to help users learn about health and
diagnosed diseases. As always be sure to discuss
matters with your doctor prior to making any
important decisions regarding therapy choices. Your
doctor knows you best.
|
|
January
New Data Support FDA Warnings about Anemia Drugs
Hepatology Expert Discusses PegIntron vs
Pegasys IDEAL Study Findings
Roche responds to announcement of 'IDEAL'
hepatitis C trial results
Stem cell therapy for chronic liver disease-choosing the right tools for the
job Commentaries -
IDEAL
Study COMMENTARY- Doug Dieterich MD A Healthy Dose of Curiosity Clinical
trial results require careful interpretation
-
SCHERING-PLOUGH REPORTS TOP-LINE RESULTS OF THE IDEAL STUDY First Large
Study Comparing Leading Hepatitis C Therapies Shows Similar Sustained
Response Rates; Fewer Patients Relapsed Following PEGINTRON Combination
Therapy -
Duration of Pegylated Interferon plus Ribavirin May Be
Tailored Based on Early Response
Long-Term Peginterferon Shows Promise Against
Hepatitis B in Pilot Study
Weight-Based Ribavirin Dosing Equals Superior
Hepatitis C Treatment
Hepatitis C virus and the controversial role of the
interferon sensitivity determining region
in the response to interferon treatment.
Eltrombopag Effective for Hepatitis C Patients With
Low Blood-Platelet Counts
|
